Compare Msci Inc (MSCI) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Msci Inc vs Neurocrine Biosciences Inc — how do they compare? Msci Inc trades at $563 (market cap $45.51B), while Neurocrine Biosciences Inc trades at $179 (market cap $17.40B). The key difference: Msci Inc is far larger — about 2.6× Neurocrine Biosciences Inc's market cap, and Msci Inc pays a 1.31% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| MSCI | NBIX | |
|---|---|---|
Market Cap | $45.51B | $17.40B |
Sector | Financials | Health |
52-Week High | $643.83 | $180.55 |
52-Week Low | $511.84 | $123.10 |
Enterprise Value | $51.67B | $16.49B |
Dividend Yield | 1.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSCI is trading at $561.74, down 10.64% today, but maintains strong fundamentals with consistent earnings beats and robust profitability. The company reported Q2 2026 EPS of $4.94, exceeding estimates of $4.90, driven by recurring subscription growth and ETF-linked AUM. Technical indicators show a bullish trend with key support at $606, while valuation ratios remain elevated with a P/E of 35.7. Recent strategic partnerships with UBS and the acquisition of First Street enhance its private markets and climate risk capabilities.
Outlook remains positive with 73% analyst buy ratings and a $725.44 consensus price target, implying 29% upside. Risks include high debt levels ($4.51B) and competitive pressures in financial data services. The stock offers growth potential through innovation and market expansion, but investors should monitor execution on strategic initiatives and margin sustainability amid economic uncertainties.
Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% today, with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with Q1 2026 EPS of $1.94 beating expectations by 59%, revenue growth to $3.1B in 2026, and net income margin expanding to 21.55%. Recent news highlights executive appointments and positive clinical trial updates for crinecerfont, supporting growth prospects.
Outlook remains positive with 86% analyst buy ratings and a $196.08 consensus price target implying 13% upside. Key risks include execution of pipeline developments and integration of acquisitions. The stock's valuation at P/E 26.62 appears reasonable given earnings growth trajectory and strong profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
